Pain · Investigational
Conantokin-G
No lawful US pathway
01 · Overview
Conantokin-G is a 17-amino acid peptide from the venom of the cone snail Conus geographus that acts as an NMDA receptor antagonist (PMID 10871336). In cells expressing defined NMDA receptor subunits, it potently inhibited receptors containing the NR2B subunit with little effect on NR2A-containing receptors (PMID 17588620).
Its gamma-carboxyglutamic acid residues support metal ion-dependent helix formation, and some of them are essential for antagonist activity (PMID 9762921). It has been studied as a potential non-opioid treatment for pain, epilepsy, and ischemic brain injury.
02 · Research summary & key findings
In mice, intrathecal conantokin-G reduced pain behavior in formalin, nerve injury, and inflammatory models at doses well below those impairing motor function (PMID 12507705). In a rat stroke model, it reduced brain infarction and improved neurological recovery, with a treatment window of several hours (PMID 10871336). It entered clinical development for epilepsy as CGX-1007 (PMID 12350382), but that development was terminated during early-phase trials (PMID 41764707). Published clinical data are lacking.
03 · Regulatory status
Conantokin-G is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Conantokin-G is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 2 FDA-approved compounds in Pain
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
Conantokin-G is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intrathecal
- Intravenous
References
- [1]Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: in vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies J Pharmacol Exp Ther, 2000. PMID 10871336
- [2]Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI) Epilepsy Res, 2002. PMID 12350382
- [3]Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T Pain, 2003. PMID 12507705
- [4]Subtype-selective antagonism of N-methyl-D-aspartate receptor ion channels by synthetic conantokin peptides Neuropharmacology, 2007. PMID 17588620
- [5]Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades Drugs, 2026. PMID 41764707
- [6]NMDA-receptor antagonist requirements in conantokin-G FEBS Lett, 1998. PMID 9762921
Primary literature
- PubMed: "Conantokin-G"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Conantokin-G"
Registered interventional and observational studies, including status and phase.
- PubChem: "Conantokin-G"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Pain
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.